The European Medicines Agency (EMA) has released Revision 24 of its nitrosamine Q&A, introducing several important updates: https://lnkd.in/gAvk967S
News & Trends
Procurar
Recentes
- Clinical evidence for orphan in vitro diagnostic medical devices
- Questions and answers for marketing authorisation holders/applicants referral on nitrosamine impurities in human medicinal products
- TEAM NB Code of Conduct for Notified Bodies vs 5.3
- GIRP POSITION PAPER: Revision of the EU Guidelines on Good Distribution Practice for Medicinal Products for Human Use
- New guidance document MDCG 2026-6 on Guidance on clinical evidence for orphan IVDs
- AI in pharmacovigilance – EMA update
- Formação ESTUDOS DE ESTABILIDADE . New ICH Q1 Guideline changes: ” Formação bastante abragente e de alto valor técnico”
- New revision of the MDCG Position Paper on the management of SS(C)P in Eudamed after mandatory use